A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

July 11, 2023

Conditions

Healthy Volunteer

Interventions

DRUG

TNB-738

TNB-738 is an investigation drug. Other: Matching placebo

DRUG

TNB-738

TNB-738 is an investigation drug. Other: Matching placebo

Trial Locations (1)

Q-Pharm Pty Ltd, Herston

All Listed Sponsors

collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

TeneoFour Inc.

INDUSTRY